US President Donald Trump recently chose an adviser to a large pharmaceutical company to lead the country’s drug regulation agency. Scott Gottlieb – who reportedly sits on the boards of several small drug companies and is an adviser to GlaxoSmithKline – is expected to introduce greater flexibility to the evidence standards used by the Food ...
Faster access to new drugs doesnt always mean better treatment
By Narcyz Ghinea and Wendy Lipworth
15 Mar 2017